Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAPOR (GETUG T06)
2023-505040-19-00Phase 2Authorised
- Sponsor
- Gustave Roussy
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cisplatin in non-seminomatous germ cell tumor (NSGCT), sponsored by Gustave Roussy. Primary endpoint: Progression-free survival (PFS). Planned start Aug 2023; status: authorised.
02
Drugs
cisplatin
03
Conditions
non-seminomatous germ cell tumor (NSGCT)
Beyond the preview
Go deeper on 2023-505040-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505040-19-00.